ERS Genomics

Applied StemCell, based in the San Francisco Bay Area, will develop and sell CRISPR-based services and reagents under a license from ERS Genomics.

The ruling is the latest decision in the fight between the Broad and the University of California for control over the bulk of the IP rights to CRISPR-Cas9.

Axxam said it will use the CRISPR technology to support the development of customized cell-based assays for targets and molecular pathways of interest.

Vienna-based Aelian combines CRISPR-Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action.

The EPO rejected arguments that were filed in opposition to the patent, which covers the use of CRISPR-Cas9 in cellular and non-cellular settings.

The European Patent Office appeals board upheld the decision made by the EPO after its initial review in 2018.

Daiichi Sankyo plans to use the ERS IP to support its own R&D initiatives to address areas of unmet medical need, the company said.

NEB plans to expand its product lines into new areas of research including genome editing, the companies said.

ERS Genomics was founded to provide access to foundational CRISPR-Cas9 IP held by Emmanuelle Charpentier for applications other than human disease treatment.